Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Sudden PSA rise to =20 ng/ml and prostate cancer diagnosis in the United States: A population-based study. The Prostate Vilson, F. L., Li, S. n., Brooks, J. D., Eisenberg, M. L. 2020

Abstract

While prostate-specific antigen (PSA) screening protocols vary, many clinicians have anecdotes of screened men with low PSA levels that rise significantly and are associated with high-risk prostate cancer (PC). We sought to better understand the frequency of high-risk cases that appear suddenly in a screened population.We utilized data from a Commercial and Medicare advantage claims database to identify all US men ages 50 and above undergoing PSA screening who then had a sudden interval rise in PSA (e.g., PSA?=?20) and diagnosis of PC. We determined associations with age, race, screening intensity, and baseline PSA levels.In all, 526,120 men met entry criteria with an average age of 60.7 and follow-up of 5.6?years. As the baseline PSA increased, the rate of high-risk PC increased from 2/10,000 persons among men with the lowest baseline PSA (<1?ng/ml) to 14/10,000 person-years among men with a baseline PSA?

View details for DOI 10.1002/pros.24075

View details for PubMedID 32956488